eli lilly glp-1 agonist As Use Expands, Long-Term Safety Questions Remain Under Watch Eli Lilly's oral GLP-1 pill

As the chart below shows, the arms race is accelerating

Drink enough water: Staying hydrated is very important for weight loss

Among the diverse array of antidiabetic agents, the class of GLP-1 receptor agonists has garnered substantial attention not only for their glycemic control properties but also for their potential cardiovascular benefits (35)

Pipeline (Phase 3 trials completed, FDA decision pending as of April 2026): Survodutide (BI 456906): Dual GLP-1/glucagon agonist from Boehringer Ingelheim

Clinical evidence The effectiveness of combination therapy with PIO (1530 mg daily) and tofogliflozin (TOFO 20 mg daily) for 24 weeks was investigated in 32 patients who experienced T2D and NAFLD in an open-label RCT [116]